团队研究方向：联合人工智能、生物信息学、神经生物学、免疫学研究脑重大疾病发病机制及潜在治疗靶点。

主要涉及一下四个方面：

（1）       人工智能在生物医学中的应用

（2）       生物信息学探讨人类疾病遗传学潜在机制

（3）       脑重大疾病脑功能异常机制与神经调控治疗方法

（4）       脑重大疾病免疫学机制及潜在治疗靶点

主持首都医科大学和北京脑重大疾病研究院课题：

1.       首都医学科学创新中心科研项目：C15orf39(1700017B05Rik)在系统性红斑狼疮B细胞中作用及机制（课题编号：CX24PY07。课题起止年限：2024年7月至2025年12月。资助金额：70万元)

2.       首都医科大学基础-临床联合实验室：脑功能与神经调控基础-临床联合实验室（课题起止年限：2024年1月至2026年12月。资助金额：300万元）

3.       首都医科大学脑重大疾病研究院科研经费（课题起止年限：2021年1月至2021年12月。资助金额：50万元）

4.       首都医科大学脑重大疾病研究院科研经费（课题起止年限：2020年1月至2020年12月。资助金额：50万元）

主持国家及北京市课题：

1.       国家自然科学基金面上项目：9430038I01Rik（C10orf143）在自身免疫病生发中心母细胞中的表达及功能（课题编号：32270933。课题起止年限：2023-01-01至2026-12-31。资助金额：54万元）

2.       北京市自然科学基金项目-北京市教育委员会科技计划重点项目：C15orf39(1700017B05Rik)在系统性红斑狼疮B细胞中作用及机制.( 课题编号： KZ202210025035。课题起止年限：2022年1月至2024年12月。资助金额：80万元)

3.       国家自然科学基金面上项目：Gm614（Cxorf65）在自身免疫病生发中心B细胞中的作用及机制（课题编号：82071758。课题起止年限：2021年1月至2024年12月。资助金额：55万元）

4.       国家自然科学基金面上项目：Stch调控生发中心B细胞反应和抗体产生的分子与细胞机制（课题编号：31770956。课题起止年限：2018年1月至2021年12月。资助金额：60万元）

5.       北京市自然科学基金面上项目：4933402N22Rik调控生发中心B细胞反应和抗体产生的机制（课题编号：7182121。课题起止年限：2018年1月至2020年12月。资助金额：20万元）

6.       国家自然科学基金面上项目：代谢型谷氨酸受体3（Grm3）在自身反应性记忆B细胞中的功能研究（课题编号：81471529。课题起止年限：2015年1月至2018年12月。资助金额：70万元）

7.       国家科技重大专项：人源化抗C5a抗体的制备及急性肺损伤中的应用（课题编号：2014ZX09J14105-04B。课题起止年限：2014年1月至2016年12月。资助金额：555.15万元）

8.       北京市自然科学基金面上项目：BAFF通过活化自身反应性B细胞引发自身免疫性疾病的机制研究（课题编号：7132139。课题起止年限：2013年1月至2015年12月。资助金额：14万元）

主持首都医科大学和北京脑重大疾病研究院课题：

1.      首都医学科学创新中心科研项目：C15orf39(1700017B05Rik)在系统性红斑狼疮B细胞中作用及机制（课题编号：CX24PY07。课题起止年限：2024年7月至2025年12月。资助金额：70万元)

2.      首都医科大学基础-临床联合实验室：脑功能与神经调控基础-临床联合实验室（课题起止年限：2024年1月至2026年12月。资助金额：300万元）

3.      首都医科大学脑重大疾病研究院科研经费（课题起止年限：2021年1月至2021年12月。资助金额：50万元）

4.      首都医科大学脑重大疾病研究院科研经费（课题起止年限：2020年1月至2020年12月。资助金额：50万元）

主持国家及北京市课题：

1.      国家自然科学基金面上项目：9430038I01Rik（C10orf143）在自身免疫病生发中心母细胞中的表达及功能（课题编号：32270933。课题起止年限：2023-01-01至2026-12-31。资助金额：54万元）

2.      北京市自然科学基金项目-北京市教育委员会科技计划重点项目：C15orf39(1700017B05Rik)在系统性红斑狼疮B细胞中作用及机制.( 课题编号： KZ202210025035。课题起止年限：2022年1月至2024年12月。资助金额：80万元)

3.      国家自然科学基金面上项目：Gm614（Cxorf65）在自身免疫病生发中心B细胞中的作用及机制（课题编号：82071758。课题起止年限：2021年1月至2024年12月。资助金额：55万元）

4.      国家自然科学基金面上项目：Stch调控生发中心B细胞反应和抗体产生的分子与细胞机制（课题编号：31770956。课题起止年限：2018年1月至2021年12月。资助金额：60万元）

5.      北京市自然科学基金面上项目：4933402N22Rik调控生发中心B细胞反应和抗体产生的机制（课题编号：7182121。课题起止年限：2018年1月至2020年12月。资助金额：20万元）

6.      国家自然科学基金面上项目：代谢型谷氨酸受体3（Grm3）在自身反应性记忆B细胞中的功能研究（课题编号：81471529。课题起止年限：2015年1月至2018年12月。资助金额：70万元）

7.      国家科技重大专项：人源化抗C5a抗体的制备及急性肺损伤中的应用（课题编号：2014ZX09J14105-04B。课题起止年限：2014年1月至2016年12月。资助金额：555.15万元）

8.      北京市自然科学基金面上项目：BAFF通过活化自身反应性B细胞引发自身免疫性疾病的机制研究（课题编号：7132139。课题起止年限：2013年1月至2015年12月。资助金额：14万元）

1.      Gao R, GaoY, Su W, Wang R*. Decoding MicroglialPolarization and Metabolic Reprogramming in Neurodegenerative Diseases:Implications for Disease Progression and Therapy. Aging Dis. 2025. Feb; 17(1):1-23. http://dx.doi.org/10.14336/AD.2024.1629. (IF: 7)

2.      Gao R*, XuY, Zhang M, Zeng Q, Zhu G, Su W*, Wang R*. From Gene Discovery to Stroke Risk: C5orf24's Pivotal Role Uncovered. MolNeurobiol. 2025 Mar 5. doi: 10.1007/s12035-025-04802-y. (IF: 4.6)

3.      Zhang M#,Su W#, Deng J#, Zhai B#, Zhu G, Gao R, Zeng Q,Qiu J, Bian Z, Xiao H, Luan G*, Wang R*. Multi-ancestry genome-wide meta-analysis with 472,819 individualsidentifies 32 novel risk loci for psoriasis. J Transl Med. 2025 Jan30;23(1):133. doi: 10.1186/s12967-024-06015-8. (IF: 6.1)

4.      Wang R*. Global burden of Alzheimer's disease and other dementias during1990-2021: a Global Burden of Disease and Risk Factors Study 2021-based study. Neuroepidemiology.2025 Jan 21:1-24. doi: 10.1159/000543578. (IF: 3.2)

5.      Xing C*, Cui H, Li G, Liu X, Liu K, Wen Q, Huang X*, Wang R*, Song L*. Hspa13 Deficiency Impaired Marginal Zone B Cells Regulatory Function andContributed to Lupus Pathogenesis. Adv Sci (Weinh). 2025 Feb;12(8):e2413144. doi:10.1002/advs.202413144. (IF: 14.3)

6.      Qiao J,Tang C, Xie M, Gong M, Fu C, Cheng Z, Chen Z, Mei A, Bo Y, Zhao M, Li T, Ji T, WangR, Deng J*, Luan G*. Aberrant activation of the mTOR signaling pathway in Rasmussenencephalitis. Sci Rep. 2025 Feb 21;15(1):6347. doi: 10.1038/s41598-025-89426-x.(IF: 3.8)

7.      Gao Z,Gao Y, Li Y, Zhou J, Li G, Xie S, Jia R, Wang L, Jiang Z, Liang M, Du C, ChenY, Liu Y, Du L, Wang C, Dou S, Lv Z, Wang L, Wang R, Shen B, WangZ, Li Y, Han G. 5-HT7R enhances neuroimmune resilience and alleviates meningitisby promoting CCR5 ubiquitination. J Adv Res. 2025 Feb;68:317-330. doi:10.1016/j.jare.2024.02.017. (IF: 11.4)

8.      Qiu J,Zhang M, Zeng Q, Zhu G, Gao R, Xiao H, Su W, Wang R. Mendelianrandomization study on causal association of IL-6 with intelligence. J Clin ExpImmunol. 2024. 9(2): 01-07.

9.      Xu Y, GaoR, Zhang M, Zeng Q, Zhu G, Qiu J, Su W*, Wang R*. Deletion of the Mitochondrial Membrane ProteinFam210b Is Associated with the Development of Systemic Lupus Erythematosus. IntJ Mol Sci. 2024 Jul 1; 25(13): 7253. doi: 10.3390/ijms25137253. (IF: 4.9).

10.   Zhang M#, Qiu J#, WangR*. Mendelian randomization study on the causaleffect of herpes simplex virus infection on idiopathic pulmonary fibrosis. ExpertRev Respir Med. 2024 May; 18(5): 341-347. doi: 10.1080/17476348.2024.2369253. (IF:2.9)

11.   Zhang M,Xu Y, Zhu G, Zeng Q, Gao R, Qiu J, Su W*, Wang R*. Human C15orf39 Inhibits Inflammatory Response via PRMT2 in HumanMicroglial HMC3 Cell Line. Int J Mol Sci. 2024 May 30; 25(11): 6025. doi: 10.3390/ijms25116025.(IF: 4.9)

12.   Zeng Q,Zhang M, Wang R*. Causal link between gut microbiomeand schizophrenia: a Mendelian randomization study. Psychiatr Genet. 2024 Apr1;34(2):43-53. doi: 10.1097/YPG.0000000000000361. (IF: 1.5)

13.   Xing C*, #, Zhai B#, Zhang Y#,Fang Y, Zhang M, Zhang C, Wang W, Ding M, Huang X, Shen B, Wang R*,Song L*. Sleep deprivation reducedLPS-induced IgG2b production by up-regulating BMAL1 and CLOCK expression.Biochem Biophys Res Commun. 2024. 691: 149326. (IF: 2.5)

14.   Chen N, WangR, Zhu W, Hao X, Wang J, Chen G, Qiao C, Li X, Liu C, Shen B, Feng J,Chai L, Yu Z, Xiao H. Development and characterization of an antibody thatrecognizes influenza virus N1 neuraminidases. PLoS One. 2024 May 9;19(5): e0302865.doi: 10.1371/journal.pone.0302865. (IF: 2.9)

15.   Xu Y*, Gao R, Zhang M, Zeng Q, Zhou S, Zhu G, Su W, Wang R. Mendelianrandomization study on causal association of FAM210B with drug-induced lupus. ClinRheumatol. 2024 May;43(5): 1513-1520. doi: 10.1007/s10067-024-06903-w. (IF: 2.9)

16.   Li Y,Wang L, Gao Z, Zhou J, Xie S, Li G, Hou C, Wang Z, Lv Z, Wang R,Han G. Neuropeptide Calcitonin Gene-Related Peptide Promotes Immune Homeostasisof Bacterial Meningitis by Inducing Major Histocompatibility Complex Class IIUbiquitination. J Infect Dis. 2024 Mar 14; 229(3): 855-865. doi:10.1093/infdis/jiad358. (IF: 5)

17.   Zhang M#, Zeng Q#, Zhou S, Zhu G, Xu Y,Gao R, Su W*, Wang R*. Mendelian randomizationstudy on causal association of IL-6 signaling with pulmonary arterialhypertension. Clin Exp Hypertens. 2023 Dec 31;45(1):2183963. doi: 10.1080/10641963.2023.2183963.(IF: 2.6)

18.   Zhang M#, Ma N#, Wang R*. Mendelian randomizationstudy on causal association of IL-6 with breast cancer. Clin Breast Cancer. 2023Jun; 23(4): e182-e188. doi: 10.1016/j.clbc.2023.01.015. (IF: 3.1)

19.   Zhou S, ZhuG, Xu Y, Gao R, Zhang M, Zeng Q, Su W*, Wang R*. Mendelian randomizationstudy on the causal effect of chickenpox on dementia. J Med Virol. 2023 Jan; 95(1):e28420. DOI: 10.1002/jmv.28420. (IF: 20.693)

20.   Zhu G*,Zhou S, Xu Y, Gao R, Zhang M, Zeng Q, Su W*, Wang R*. Chickenpoxand multiple sclerosis: A Mendelian randomization study. J Med Virol. 2023 Jan;95(1): e28315. doi: 10.1002/jmv.28315. (IF: 20.693)

21.   Zhang J,Wang X, Wang R, Chen G, Wang J, Feng J, Li Y, Yu Z, Xiao H. RapamycinTreatment Alleviates Chronic GVHD-Induced Lupus Nephritis in Mice by RecoveringIL-2 Production and Regulatory T Cells While Inhibiting Effector T CellsActivation. Biomedicines. 2023. 11(3): 949.https://doi.org/10.3390/biomedicines11030949. (IF: 4.757)

22.   Liu X, WangJ, Shen L, Wang R, Zhang L, Li C. Single-cell atlas reveals ahigh selection of IgA1- or IgG1-expressing plasma cells in patients with psoriasis.Mol Immunol. 2023 Jan; 153: 85–93. (IF: 4.174)

23.    Su W, Zhou S, Zhu G, Xu Y, Gao R, Zhang M, Zeng Q, WangR*. Mendelian randomization study on causal association ofpyroglutamine with COVID-19. J Epidemiol Glob Health. 2022 Dec; 12(4): 541-547.doi: 10.1007/s44197-022-00073-1. (IF:5.959)

24.    Ma N, Wang R*. Mendelian randomizationstudy on the effect of tumor necrosis factor on schizophrenia. Psychiat Genet. 2022Dec 1; 32(6): 238-245. doi: 10.1097/YPG.0000000000000329. (IF: 2.574)

25.    Zhu G#, Zhou S#, Xu Y, Gao R,Li H, Su W*, Han G*, Wang R*. Mendelian randomization study on thecausal effects of COVID-19 on childhood intelligence. J Med Virol. 2022 Jul.94(7): 3233-3239. doi: 10.1002/jmv.27736. (IF: 20.693)

26.    Zhou S#, Zhu G#, Xu Y, Gao R,Li H, Han G*, Su W*, Wang R*. Mendelian randomization study on the putative causal effects of omega-3fatty acids on low back pain. Front Nutr. 2022. Feb 14. 9: 819635. doi:10.3389/fnut.2022.819635. (IF: 6.590)

27.   Gao R#,Xu Y#, Zhu G, Zhou S, Li H, Han G*, Su W*, Wang R*. Geneticvariation associated with COVID-19 is also associated with endometrial cancer. JInfect. 2022 Jan 22. 84(5): e85-6. doi: 10.1016/j.jinf.2022.01.026. (IF: 38.637)

28.   Xu Y#,Gao R#, Zhu G, Zhou S, Li H, Su W*, Han G*, Wang R*.Genetic variation associated with allergic disease is also associated withsusceptibility to COVID-19. J Infect. 2022. Jan 14. 84(5): e92-3. doi:10.1016/j.jinf.2022.01.015. (IF: 38.637)

29.   Zhu G#,Zhou S#, Xu Y, Gao R, Li H, Zhai B, Liu X, He Y, Wang X, Han G*, SuW*, Wang R*. Mendelian randomization study on the causal effects ofomega-3 fatty acids on rheumatoid arthritis. Clin Rheumatol. 2022 May. 41(5): 1305-1312.doi: 10.1007/s10067-022-06052-y (IF: 3.650)

30.   Wang R*. Genetic variation of interleukin-1 receptor type1 is associated with severity of COVID-19 disease. J Infect. 2022. Feb. 84(2):e19–e21. doi: 10.1016/j.jinf.2021.12.010. (IF: 38.637)

31.   Wang R*. Mendelian randomization study updates the effectof 25-hydroxyvitamin D levels on the risk of multiple sclerosis. J Transl Med.2022. Jan 3. 20(1): 3. doi: 10.1186/s12967-021-03205-6. (IF:8.440) (高被引论文)

32.   Zhai B#,Liu X#，Xu Y#, Zhu G, Zhou S, He Y, Wang X, Su W*, Han G*, Wang R*.Single-cell atlas of splenocytes reveals a critical role of a novel plasma cell‒specificmarker Hspa13 in antibody class-switching recombination and somatichypermutation. Mol Immunol. 2022. Jan. 141: 79–86. https://doi.org/10.1016/j.molimm.2021.11.014(IF: 4.174)

33.   Tang L#,Li G#, Zheng Y, Hou C, Gao Y, Hao Y, Gao Z, Mo R, Li Y, Shen B, WangR*, Wang Z*, Han G*. Tim-3 Relieves Experimental AutoimmuneEncephalomyelitis by Suppressing MHC-II. Front Immunol. 2022. Jan 13. 12: 770402.doi: 10.3389/fimmu.2021.770402. (IF: 8.786)

34.   Shi Q,Li G, Dou S, Tang L, Hou C, Wang Z, Gao Y, Gao Z, Hao Y, Mo R, Shen B, WangR, Li Y*, Han G*. Negative Regulation of RIG-I by Tim-3 Promotes H1N1Infection. Immunol Invest. 2022. Aug. 23:1-19. doi:10.1080/08820139.2022.2113407. (IF: 3.044)

35.    Zhou S, Wang R*. Targeted therapy ofmultiple myeloma. Explor Target Antitumor Ther. 2021;2:465-80.https://doi.org/10.37349/etat.2021.00057.

36.    He Y#, Fang Y#, Zhai B#,Liu X#, Zhu G#, Zhou S, Xu Y, Wang X, Su W*, Wang R*.Gm40600 promotes CD4+T cell responses by interacting with Ahnak. Immunology.2021. Sep. 164:190–206. DOI: 10.1111/imm.13365. (IF: 7.397)

37.    Fang Y#, He Y#, Zhai B#,Hou C#, Xu R, Xing C, Wang X, Ma N, Han G*, Wang R*. The E3 ubiquitin ligase Itch deficiency promotesantigen-driven B-cell responses in mice. Eur J Immunol. 2021. 51(1): 103-114.DOI:10.1002/eji.202048640. (IF: 5.532)

38.    Li G, Tang L, Hou C, Wang Z, Gao Y, Dou S, Mo R,Hao Y, Gao Z, Li Y, Dong J, Zhang J, Shen B, Wang R*, Han G*.Peripheral Injection of Tim-3 Antibody Attenuates VSV Encephalitis by EnhancingMHC-I Presentation. Front Immunol. 2021. 12: 667478. doi:10.3389/fimmu.2021.667478. (IF: 7.561)

39.   Zhang J,Hou C, Dou S, Li G, Wang Z, Liu Y, Zhang Y, Wang R*, Shen B, Han G*. T cell immunoglobulin and mucin domain protein 3inhibits glycolysis in RAW 264.7 macrophages through Hexokinase 2. Scand JImmunol. 2021 Feb;93(2): e12981. doi: 10.1111/sji.12981. (IF: 3.487)

40.   Dou S,Li G, Li G, Hou C, Zheng Y, Tang L, Gao Y, Mo R, Li Y, Wang R*,Shen B, Zhang J*, Han G*. Ubiquitination and degradation of NF90 by Tim-3inhibits antiviral innate immunity. Elife. 2021 Jun 10; 10: e66501. doi:10.7554/eLife.66501. (IF: 8.140)

41.   He Y#,Xu R#, Zhai B#, Zhou S, Wang X, Wang R*. Gm614 protects germinal center B cells from deathby suppressing caspase-1 transcription in lupus-prone mice. Front Immunol.2020. 11:585726. doi: 10.3389/fimmu.2020.585726. (IF:5.085)

42.   He Y,Zhai B, Zhou S, Wang X, Wang R*.Chemokine-Expressing Th1 and Treg Cells are Increased in the Lung of Patientswith COVID-19. Available at SSRN: https://ssrn.com/abstract=3629437 orhttp://dx.doi.org/10.2139/ssrn.3629437.

43.   Zhai B#,He Y#, Zhou S#, Wang X, Wang R*. Characterization of Lung Bronchoalveolar HumoralImmunity in Patients with COVID-19. Adv Clin Transl Res. 2020. 4: 100026.

44.   He Y#,Xu R#, Zhai B#, Fang Y#, Hou C#,Xing C, Xiao H, Chen G, Wang X, Ma N, Han G*, Wang R*. Hspa13 promotes plasma cell production and antibodysecretion. Front Immunol. 2020. 11:913. (IF: 5.085)

45.   Zhai B#, Hou C#, Xu R#, Fang Y#, Ma N, Xing C, Wang X,Xiao H, Chen G, Han G*, Wang R*. Gm6377 suppressed SP 2/0xenograft tumor by down-regulating Myc transcription. Clin Transl Oncol. 2020. Sep.22(9):1463-1471. (IF: 2.737)

46.   Wang Z,Li G, Dou S, Zhang Y, Liu Y, Zhang J, Li G, Hou C, Wang R, Shen B, Han G. Tim-3 Promotes Listeria monocytogenesImmune Evasion by Suppressing Major Histocompatibility Complex Class I. JInfect Dis. 2020 Feb 18; 221(5): 830-840. (IF: 5.022)

47.   Fang Y, Xu R, Zhai B, Hou C, Ma N,Wang L, Han G, Jiang Z*, Wang R*. Gm40600 suppressed SP 2/0isograft tumor by reducing Blimp1 and Xbp1 proteins. BMC Cancer. 2019 Jul 16.19(1):700. (IF: 2.933)

48.   Wei Y#,Zhang F#, Zhang Y#, Wang X, Xing C, Guo J, Zhang H, SuoZ, Li Y, Wang J, Wang R*, CaiZ*. Post-transcriptional regulator Rbm47 elevates IL-10 production and promotesthe immunosuppression of B cells. Cell Mol Immunol. 2019 Jun; 16(6):580-589.(IF: 7.551)

49.   Zhai B#, Hou C#, Xu R#, Fang Y#, Xiao H, Chen G, Wang X,Ma N, Han G*, Wang R*. Loc108167440 suppressed myeloma cell growth by p53-mediated apoptosis.Leuk Lymphoma. 2019. Oct; 60 (10): 2541-2548. (IF: 2.674)

50.   Liu X#,Zhang Y#, Wei Y#, Wang Z, Zhu G, Fang Y, Zhai B, Xu R,Han G, Chen G, Xiao H, Hou C, Shen B, Li Y, Ma N *, Wang R *. The E3 ubiquitin ligase Itch is required forB-cell development. Sci Rep. 2019. Jan 23. 9(1): 421. (IF: 4.011)

51.   Ma N#, Fang Y#, Xu R, Zhai B, Hou C, Wang X, Jiang Z, Wang L, LiuQ *, Han G *, Wang R *. Ebi3 promotes T- and B-cell division and differentiation via STAT3. MolImmunol. 2019. Jan 18. 107: 61-70. (IF: 3.064)

52.   Li G,Hou C, Dou S, Zhang J, Zhang Y, Liu Y, Wang Z, Xiao H, Wang R*, Chen G, Li Y, Feng J, Shen B, Han G*. Monoclonalantibody against human Tim-3 enhances antiviral immune response. Scan JImmunol. 2019 Feb; 89(2):e12738. (IF: 2.563)

53.   Lv Z,Wang Z, Luo L, Chen Y, Han G, Wang R,Xiao H, Li X, Hou C, Feng J, Shen B, Wang Y, Peng H, Guo R, Li Y, Chen G.Spliceosome protein Eftud2 promotes colitis-associated tumorigenesis bymodulating inflammatory response of macrophage. Mucosal Immunol. 2019Sep;12(5):1164-1173. (IF: 7.352)

54.   Xu R#,Fang Y#, Hou C#, Zhai B#, Jiang Z, Ma N, WangL *, Han G *, Wang R *.BC094916 suppressed SP 2/0 xenograft tumor by down-regulating Creb1 and Bcl2transcription. Cancer Cell Int. 2018. Sep 14; 18:138. (IF: 3.96)

55.   Zhu G#,Liu X#, Fang Y#, Zhai B, Xu R, Han G, Chen G, Xiao H, HouC, Shen B, Li Y, Iwakura Y, Wang L, Jiang Z, Ma N *, Liu G*, Wang R*. Increased mTOR cancelsout the effect of reduced Xbp-1 on antibody secretion in IL-1α-deficient Bcells. Cell Immunol. 2018. Feb 24. 328: 9-17. (IF: 2.995)

56.   Wang X#,Zhang Y#, Wang Z#, Liu X, Zhu G, Han G, Chen G, Hou C, Wang T, Shen B, Li Y, Xiao H, Ma N*,Wang R*. Anti-IL-39(IL-23p19/Ebi3) polyclonal antibodies ameliorate autoimmune symptoms inlupus-like mice. Mol Med Rep. 2018. Jan. 17(1): 1660-1666. (IF:1.922)

57.   Sun S#,Jiang Y#, Wang R#,Liu C, Liu X, Song N, Guo Y, Guo R, Du L, Jiang S, Li Y, Qiu Z*,Zhao G*, Zhou Y*. Treatment of paraquat-induced lunginjury with an anti-C5a antibody: potential clinical application. Crit CareMed. 2018. May. 46(5): e419-e425. (IF: 6.630)

58.   Wang W,Shi Q, Dou S, Li G, Shi X, Jiang X, Wang Z, Yu D, Chen G, Wang R, Xiao H, Hou C, Feng J, Shen B, Ma Y, Han G. Negativeregulation of Nod-like receptor protein 3 inflammasome activation by T cell Igmucin-3 protects against peritonitis. Immunology. 2018. Jan. 153 (1): 71-83.(IF: 3.358)

59.   Zhang Y#,Zhu G#, Xiao H#, Liu X, Han G, Chen G, Hou C, Shen B, LiY, Ma N*, Wang R*.CD19 regulates ADAM28-mediated Notch2 cleavage to control the differentiationof marginal zone precursors to MZ B cells. J Cell Mol Med. 2017. Jul 14. 21(12): 3658-3669. (IF: 4.499)

60.   Xing C#,Zhu G#, Xiao H#, Fang Y, Liu X, Han G, Chen G, Hou C,Shen B, Li Y, Ma N*, WangR*. B cells regulated thymic CD8+T celldifferentiation in lupus-prone mice. Oncotarget. 2017. Jul 5. 8 (52):89486-89499. (IF: 5.168)

61.   Zhu G #,Wang X #, Xiao H #, Liu X, Fang Y, Zhai B, Xu R, Han G,Chen G, Hou C, Shen B, Li Y, Ma N, Wu H*, Liu G*, Wang R*. Both Notch1 and its ligands in B cells promoteantibody production. Mol Immunol. 2017. Aug 29; 91: 17-23. (IF: 3.236)

62.   Zhang Y#,Wang Z#, Xiao H#, Liu X, Zhu G, Han G, Chen G, Hou C, MaN, Shen B, Li Y, Wang T *, Wang R*.Foxd3 suppresses interleukin-10 expression in B cells. Immunology 2017. Apr.150(4): 478-488. (IF: 3.701)

63.   Ma N#,Zhang Y#, Liu Q#, Wang Z, Liu X, Zhu G, Yu D, Han G, ChenG, Hou C, Wang T, Ma Y, Shen B, Li Y, Xiao H*, Wang R*. B cell activating factor (BAFF) selects IL-10 -B cells over IL-10 + B cells during inflammatory responses. MolImmunol. 2017. Feb. 85: 18-26. (IF: 3.236)

64.   DambuzaIM, He C, Choi JK, Yu CR, Wang R,Mattapallil MJ, Wingfield PT, Caspi RR, Egwuagu CE. IL-12p35 induces expansionof IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmunedisease. Nat Commun. 2017 Sep 28; 8(1):719. (IF:12.124)

65.   Chen Y,Zhao Z, Chen Y, Lv Z, Ding X, Wang R,Xiao H, Hou C, Shen B, Feng J, Guo R, Li Y, Peng H, Han G, Chen G. Anepithelial-to-mesenchymal transition-inducing potential of granulocytemacrophage colony-stimulating factor in colon cancer. Sci Rep. 2017 Aug 15;7(1): 8265. (IF: 4.259)

66.   Wang Z,Sun D, Chen G, Li G, Dou S, Wang R,Xiao H, Hou C, Li Y, Feng J, Shen B, Han G. Tim-3 inhibits macrophage controlof Listeria monocytogenes by inhibiting Nrf2. Sci Rep. 2017 Feb 16; 7: 42095. (IF: 4.259)

67.   Li Y,Zhou T, Wang Y, Ning C, Lv Z, Han G, Morris JC, Taylor EN, Wang R, Xiao H, Hou C, Ma Y, Shen B, Feng J, Guo R, Li Y,Chen G. The protumorigenic potential of FTY720 by promoting extramedullaryhematopoiesis and MDSC accumulation. Oncogene. 2017 Jun 29. 36(26):3760-3771. (IF: 7.519)

68.   Wang X,Liu X, Zhang Y, Wang Z, Zhu G, Han G, Chen G, Hou C, Wang T, Ma N, Shen B, LiY, Xiao H*, Wang R*.Interleukin (IL)-39 [IL-23p19/Epstein–Barr virus-induced 3 (Ebi3)] inducesdifferentiation/expansion of neutrophils in lupus-prone mice. Clin Exp Immunol.2016 Nov. 186 (2): 144-156. (IF: 3.148)

69.   Liu X,Zhang Y, Wang Z, Wang X, Zhu G, Han G, Chen G, Hou C, Wang T, Shen B, Li Y, MaN, Xiao H*, Wang R*.Metabotropic glutamate receptor 3 is involved in B-cell-related tumor apoptosis.Int J Oncol. 2016 Oct. 49 (4): 1469-1478. (IF: 3.018)

70.   Wang X#, Wei Y#, Xiao H#, Liu X, Zhang Y, Han G, Chen G, Hou C, Ma N, Shen B, Li Y,Egwuagu CE, Wang R*. Novel IL-23p19/Ebi3(IL-39) Cytokine Mediates Inflammation in Lupus-like Mice. Eur J Immunol. 2016Jun; 46(6): 1343-1350. (IF: 4.179)

71.   Wang X#, Wei Y#, Xiao H#, Liu X, Zhang Y, Han G, Chen G, Hou C, Zhang L, Ma N, Shen B, Li Y, Egwuagu CE*, Wang R*. Pre-existing CD19-independent GL7- Breg cells are expanded duringinflammation and in mice with lupus-like disease. Mol Immunol. 2016 Mar; 71:54-63. (IF: 3.375)

72.   Jiang X,Zhou T, Xiao Y, Yu J, Dou S, Chen G, WangR, Xiao H, Hou C, Wang W, Shi Q, Feng J, Ma Y, Shen B, Li Y, Han G.Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1and suppressing the STAT1-miR-155 signaling axis. OncoImmunology. 2016. Aug 3,5(9): e1211219. (IF: 7.644)

73.   Ma N#,Liu X#, Xing C#, Wang X, Wei Y, Han G, Chen G, Hou C,Shen B, Li Y, Xiao H*, WangR*. Ligation of metabotropic glutamate receptor 3 (Grm3)ameliorates lupus-like disease by reducing B cells. Clin Immunol. 2015 Jun 9;160(2): 142-154. (IF: 3.672)

74.   Wang X#,Wei Y#, Liu X#, Xing Chen, Han G, Chen G, Hou C, DambuzaIM, Shen B, Li Yan, Xiao H*, WangR*. IL-15-secreting γδT cells induce memory T cells inexperimental allergic encephalomyelitis (EAE) mice. Mol Immunol. 2015 Aug; 66(2):402-408. (IF: 2.973)

75.   Wang R, Xiao H, Guo R, Li Y*, Shen B*. The role of C5a in acute lung injury induced by highly pathogenic viralinfections. Emerg Microbes Infect. 2015 May; 4(5): e28. Review (IF: 2.258)

76.   Wang X, XiaoH, Wei Y, Liu X, Han G, Chen G, Hou C, Shen B, Li Y, Wang R*. Blockade of B-cell activating factorwith TACI-IgG effectively reduced Th1 and Th17 cells but not memory T cells inexperimental allergic encephalomyelitis mice. Central Eur J Immunol. 2015. 40(2): 142-148 (IF: 0.28)

77.   Xing C, MaN, Xiao H, Wang X, Zheng M, Han G, Chen G, Hou C, Shen B, Li Y*, Wang R*. Criticalrole for thymic CD19+CD5+CD1dhiIL-10+regulatory B cells in immune homeostasis. J Leukoc Biol. 2015 Mar; 97(3):547-556.(IF: 4.289)

78.   He Y#,Ma N#, Xing C, Wang X, Xiao H, Zheng M, Han G, Chen G, Hou C, ShenB, Li Y, Jiang Z*, Wang R*,Wu W*. Novel IL-6-secreting γδT cells increased in patients withatherosclerotic cerebral infarction. Mol Med Rep. 2015 Feb; 11(2): 1497-1503. (IF: 1.554)

79.   EgwuaguCE, Yu CR, Sun L, Wang R.Interleukin 35: Critical Regulator of Immunity and Lymphocyte-mediated Diseases.Cytokine Growth F R. 2015. Oct; 26 (5): 587-593. Review (IF: 5.357).

80.   Ning C,Li YY, Wang Y, Han GC, Wang RX,Xiao H, Li XY, Hou CM, Ma YF, Sheng DS, Shen BF, Feng JN, Guo RF, Li Y, ChenGJ. Complement activation promotes colitis-associated carcinogenesis throughactivating intestinal IL-1β/IL-17A axis. Mucosal Immunol. 2015 Nov; 8(6):1275-84. (IF: 7.374)

81.   Jiang X,Yu J, Shi Q, Xiao Y, Wang W, Chen G, Zhao Z, Wang R, Xiao H, Hou C, Feng J, Ma Y, Shen B, Wang L, Li Y,Han G. Tim-3 promotes intestinal homeostasis in DSS colitis by inhibiting M1polarization of macrophages. Clin Immunol. 2015 Jul 21; 160: 328–335. (IF:3.672)

82.   Sun S,Zhao G, Liu C, Fan W, Zhou X, Zeng L, Guo Y, Kou Z, Yu H, Li J, Wang R, Li Y, Schneider C, HabelM, Riedemann NC, Du L, Jiang S, Guo R, Zhou Y. Treatment With Anti-C5a AntibodyImproves the Outcome of H7N9 Virus Infection in African Green Monkeys. ClinInfect Dis. 2015 Feb 15; 60(4): 586-95. (IF: 8.886)

83.   Zheng M#,Xing C#, Xiao H#, Ma N, Wang X, Han G, Chen G, Hou C,Shen B, Li Y*, Wang R*.Interaction of CD5 and CD72 is involved in regulatory T and B cell homeostasis.Immunol Invest. 2014. 43:705-716. (IF: 1.903)

84.   Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska M,Sergeey YV, Wingfield PT, Kim SH, Egwuagu CE*. Interleukin-35 induces regulatory B cells thatsuppress autoimmune disease. Nat Med. 2014. 20: 633-641. (IF: 28.054) (高被引论文)

85.   Ma N#,Xing C#, Xiao H#, He Y, Han G, Chen G,Hou C, Marrero B, Wang Y, Zhang S, Shen B, Li Y*, Wang R*. BAFFSuppresses IL-15 Expression in B Cells. J Immunol. 2014. 192: 4192-4201. (IF: 5.362)

86.    Ma N#, He Y#, Xiao H#,Han G, Chen G, Wang Y, Wang K, Hou C, Yang X, Marrero B, Wang Y, Shen B, Li Y*,Wang R*. BAFFMaintains T-Cell Survival by Inducing OPN Expression in B Cells. Mol Immunol.2014. 57: 129-137. (IF: 3.003)

87.    Ma N, Xiao H, Marrero B, Xing C, Wang X, Zheng M,Han G, Chen G, Hou C, Shen B, Li Y, WangR，Jiang Z*. Combination of TACI-IgG and Anti-IL-15 Treats MurineLupus by reducing mature and memory B cells. Cell Immunol. 2014. 289: 140-144. (IF: 1.874)

88.   Zhao Z,Jiang X, Kang C, Xiao Y, Hou C, Yu J, WangR, Xiao H, Zhou T, Wen Z, Feng J, Chen G, Ma Y, Shen B, Li Y, Han G. Blockadeof the T cell immunoglobulin and mucin domain protein 3 pathway exacerbatessepsis-induced immune deviation and immunosuppression. Clin Exp Immunol. 2014 Nov.178 (2): 279-91.  (IF: 3.278)

89.   Wang Y,Han G, Wang K, Liu G, Wang R, Xiao H, Li X, Hou C, Shen B, Guo R,Li Y, Chen G. Tumor-derived GM-CSF promotes inflammatory colon carcinogenesisvia stimulating epithelial release of VEGF. Cancer Res. 2014. 74: 716-726. (IF: 9.284)

90.    Wang Y, Wang K, Han GC, Wang R,Xiao H, Hou CM, Guo RF, Dou Y, Shen BF, Li Y, Chen GJ. Neutrophil infiltrationfavors colitis-associated tumorigenesis by activating the interleukin-1(IL-1)/IL-6 axis. Mucosal Immunol. 2014. Sep. 7(5): 1106-15. (IF: 7.537)

91.    Guo X, Jiang X, Xiao Y, Zhou T, Guo Y, WangR, Zhao Z, Xiao H, Hou C, Ma L, Lin Y, Lang X, Feng J, Chen G, Shen B,Han G, Li Y. IL-17A signaling in colonic epithelial cells inhibitspro-inflammatory cytokine production by enhancing the activity of ERK and PI3K.PLoS One. 2014. 9: e89714. (IF: 3.534)

92.    He Y#, Ma N#, Xiao H#,Xing C, Han G, Chen G, Hou C, Shen B, Li Y, Wang R*, Hu W. BAFF induces the transcription ofrecombination-activating genes in transitional stage 1 B cells. Centr Eur J Immunol. 2013. 38 (3):336-342. (IF: 0.378)

93.    Ma N#, Xing C#, Xiao H#,Wang Y, Wang K, Hou C, Han G, Chen G, Marrero B, Wang Y, Shen B, Li Y*, Wang R*. C5a regulates IL-12+DC migration to inducepathogenic Th1 and Th17 cells in sepsis. Plos one. 2013. 8(7): e69779. (IF: 3.73)

94.    Wang R#, Wang R#,Ma N, Guo Y, Xiao H, Chen G, Han G, Hou C, Shen B, Feng J*, Li Y*. Identify the key amino acid of BAFF binding with TACI. Cell Immunol. 2013.284：84-90. (IF:1.743)

95.    Wang Y, Han G, Chen Y, Wang K, Liu G, Wang R, Xiao H, Li X, Hou C,Shen B, Guo R, Li Y, Chen G. Protective role of tumor necrosis factor (TNF)receptors in chronic intestinal inflammation: TNFR1 ablation boosts systemicinflammatory response. Lab Invest. 2013. 93(9):1024-1035. (IF: 3.961)

96.    Yang X, Jiang X, Chen G, Xiao Y, Geng S, Kang C, Zhou T, Li Y, Guo X, XiaoH, Hou C, Wang R, Lin Z, LiX, Feng J, Ma Y, Shen B, Li Y, Han G. T Cell Ig Mucin-3 Promotes Homeostasis ofSepsis by Negatively Regulating the TLR Response. J Immunol. 2013. 190:2068-79. (IF: 5.52)

97.   Wang RX, Yu CR, Mahdi RM, Egwuagu CE. NovelIL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis byinhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory Tcells. J Biol Chem. 2012. 287: 36012-21. (IF: 4.773)

98.   Wang YJ, Shen DF, Wang VM, Yu CR, Wang R, Tuo JS, Chan CC.Enhanced apoptosis in retinal pigment epithelium under inflammatory stimuli andoxidative stress. Apoptosis. 2012. 17: 1144-55. (IF: 4.788)

99.   Wang K, Han G, Dou Y, Wang Y, LiuG, Wang R, Xiao H, Li X, HouC, Shen B, Guo R, Li Y, Shi Y, Chen G. Opposite role of tumor necrosis factorreceptors in dextran sulfate sodium-induced colitis in mice. PLoS One. 2012. 7:e52924. (IF: 4.537)

100.Shi F, GuoX, Jiang X, Zhou P, Xiao Y, Zhou T, Chen G, Zhao Z, Xiao H, Hou C, Li X, YangX, Wang R, Feng J, Shen B, LiY, Han G. Dysregulated Tim-3 expression and its correlation with imbalanced CD4helper T cell function in ulcerative colitis. Clin Immunol. 2012. 145: 230-40.(IF: 4.046)

101.Yang Y, Wang H, Dou Y, Wang Y, Han G, WangR, Wang L, Guo R, Xiao H, Li X, Shen B, Shi Y, Chen G, Li Y.Colitogenic role of tumour necrosis factor (TNF) receptors in trinitrobenzenesulphonic acid colitis: TNF-R1 ablation does not affect systemic inflammatoryresponse. Clin Exp Immunol. 2011 Sep. 165: 372-82. (IF: 3.134)

102.Han G, Geng S, Li Y, Chen G, Wang R,Li X, Ma Y, Shen B, Li Y. γδT-cell function in sepsis is modulated by C5a receptor signalling. Immunology. 2011Jul. 133: 340-9. (IF: 3.302)

103.Li Y, Feng J, Geng S, Geng S, Wei H, Chen G, Li X, Wang L, Wang R, Peng H, Han G, Shen B, Li Y. The N-and C-terminal carbohydrate recognition domains of galectin-9 contributedifferently to its multiple functions in innate immunity and adaptive immunity.Mol Immunol. 2011 Jan. 48: 670-7. (IF: 2.916)

104.Chen G, Yang Y, Gao X, Dou Y, Wang H, Han G, WangR, Wang J, Wang L, Li X, Guo R, Xiao H, Shen B, Li Y. Blockade of complementactivation product C5a activityusing specific antibody attenuates intestinal damage in trinitrobenzenesulfonic acid induced model of colitis. Lab Invest. 2011 Mar. 91: 472-83. (IF:4.405)

105.Xu R#, Wang R #, Han G #, Wang J, Chen G, Wang L, Li X, Guo R, Shen B, Li Y. Complement C5aregulates IL-17 by affecting the crosstalk between DC and gammadelta T cells inCLP-induced sepsis. Eur J Immunol. 2010. 40: 1079-88. (IF: 4.942)

106.Han G, Wang R #, Chen G #, Wang J, Xu R, Wang L, Feng J, Li X, Guo R, Fu L, Shen B, Li Y.Interleukin-17-producing gammadelta (+) T cells protect NOD mice from type Idiabetes through a mechanism involving transforming growth factor-beta.Immunology. 2010. 129: 197-206. (IF: 3.302)

107.Wang L, Han G, Wang R,Chen G, Xu R, Xiao H, Li X, Geng S, Li Y, Li X, Wang J, Feng J, Riedemann NC,Guo R, Shen B, Li Y. Regulation of IL-8 production by complement activatedproduct, C5a, in vitroand in vivo during sepsis. Clin Immunol. 2010 Oct; 137(1):157-65. (IF:3.932)

108.Li X, Chen G, Li Y, Wang R, Wang L, Lin Z, Gao X, Feng J, MaY, Shen B, Li Y, Han G. Involvement of T cell Ig Mucin-3 (Tim-3) in thenegative regulation of inflammatory bowel disease. Clin Immunol. 2010. 134:169-177. (IF: 3.932)

109.Wang R#, Han G #, Song L, Wang J, Chen G, Xu R, Yu M, Qian J, Shen B, Li Y. CD8+ regulatoryT cells are responsible for GAD-IgG gene-transferred tolerance induction in NODmice. Immunology. 2009. 126: 123-131. (IF: 3.398)

110.Wang R, Gencheng Han, Jianan Wang, Guojiang Chen,Ruonan Xu,Liyan Wang, Xia Li, Beifen Shen and Yan Li. Foxp3-mediated immunityof human pancreatic cancer cell line PANC-1. Am J Immunol. 2009. 5: 101-107.

111.Chen G, Han G, Feng J, Wang J, Wang R, Xu R, Shen B, Qian J,Li Y. Glutamic acid decarboxylase-derived epitopes with specific domains expandCD4+CD25+ regulatory T cells. Plos One. 2009. 13: e7034.

112.Chen G, Han G, Wang J, Wang R, Xu R, Shen B, Qian J, Li Y.Natural killer cells modulate overt autoimmunity to homeostasis in nonobesediabetic mice after anti-CD3 F(ab’)2antibody treatment through secreting transforming growth factor-beta. Am JPathol. 2009. 175: 1086-1094. (IF:5.487)

113.Wang R#, Han G #, Wang J, Chen G, Xu R, Wang L, Li X, Shen B, Li Y. The pathogenic role ofinterleukin-27 in autoimmunediabetes. Cell Mol Life Sci. 2008. 65: 3851-3860. (IF: 5.239)

114.Wang R #, Han G #, Wang J, Song L, Chen G, Xu R, Wang L, Li X, ShenB, Li Y. Diabetes is not prevented by Foxp3-transduced CD4(+)T cells under theIL-12Rbeta2 promoter control. Mol Immunol. 2008. 45: 3814-3817. (IF: 3.742)

115.Wang R#, Han G#, Wang J, Song L, Chen G, Xu R, Zhang C, Yu M, Qian J, Shen B, Li Y.GAD-IgG-inducing CD4+Foxp3+Treg cells suppressing diabetes is involved in theincreasing ratio of CD80+: CD86+ cells in NOD mice. Arch Med Res. 2008. 39:299-305. (IF: 1.772)

116.Han G#, Wang R #, Chen G #, Wang J, Xu R, Feng J, Yu M, Wu X, Qian J, Shen B, Li Y. Gene delivery GAD500 autoantigen by AAV serotype 1 prevented diabetes in NOD mice: transductionefficiency do not play important roles. Immunol Lett. 2008. 115:110-116.(IF:2.628)

117.Chen G, Han G, Wang J, Wang R, Xu R, Shen B, Qian J, Li Y. Inductionof active tolerance and involvement of CD1d-restricted natural killer T cellsin anti-CD3 F(ab')2 treatment-reversed new-onset diabetes in nonobese diabeticmice. Am J Pathol. 2008. 172: 972-979. (IF:5.487)

118.Chen G, Han G, Wang J, Wang R, Xu R, Shen B, Qian J, Li Y.Essential roles of TGF-{beta} inanti-CD3 antibody therapy: reversal of diabetes in nonobese diabetic miceindependent of Foxp3+CD4+ regulatory T cells. J Leukoc Biol. 2008. 83: 280-287.(IF: 4.128)

119.Wang R #, Han G #, Wang J, Song L, Chen G, Xu R, Yu M, Qian J, ShenB, Li Y. Foxp3-expressing CD4(+)T cells under the control of INF-gamma promoterprevent diabetes in NOD mice. Mol Ther. 2007. 15: 1551-1557. (IF: 5.841)

120.Wang R #, Song L #, Han G #, Wang J, Chen G, Xu R, Yu M, Qian J, Shen B, Li Y.Mechanisms of regulatory T cell induction by antigen-IgG-transducedsplenocytes. Scand J Immunol. 2007. 66: 515-522. (IF: 2.09)

121.Wang R #, Han G #, Wang J, Song L, Chen G, Xu R, Yu M, Qian J, ShenB, Li Y. The role of STAT3 inantigen-IgG inducing regulatory CD4+Foxp3+T cells. Cell Immunol. 2007. 246:103-109. (IF: 1.709)

122.Wang R #, Han G #, Wang J, Song L, Chen G, Xu R, Yu M, Qian J, ShenB, Li Y. Mechanisms underlying B-cell tolerance induction byantigen-immunoglobulin G gene transfer. J Int Med Res. 2007. 35: 781 –789. (IF:0.665)

123.Zhang C, Xu R, Wang J, Han G, Chen G, Wang R, Huawei Wei,Beifen Shen, Yuanfang Ma and Yan Li. Functional identification of the stabletransfection C5aR cell line Molt-4. Cell Mol Immunol. 2007. 4: 461-465.

124.Han G, Li Y, Wang J, Wang R, Chen G, Song L, Xu R, Yu M, WuX, Qian J, Shen B. Active tolerance induction and prevention of autoimmunediabetes by immunogene therapy using recombinant adenoassociated virusexpressing glutamic acid decarboxylase 65 peptide GAD(500-585). J Immunol.2005. 174: 4516-4524. (IF:6.702)

125.Xu R, Wang J, Chen G, Han G, Wang R, Shen BF, Li Y. Theeffects of CD3-Specific Molecular Antibody on Treating Experimental Autoimmune MyastheniaGravis. Cell Mol Immunol. 2005. 2: 461-465.

126.Song L, Wang J, Wang R, Yu M, Sun Y, Han G, Li Y, Qian J,Scott DW, Kang Y, Soukhareva N, Shen B. Retroviral delivery of GAD-IgG fusion constructinduces tolerance and modulates diabetes: a role for CD4+ regulatory T cellsand TGF-beta? Gene Ther. 2004. 11:1487-1496. (IF:5.237)

1.  王仁喜。癫痫专业委员会分会报告：B细胞在多发性硬化中的作用及机制。2023年北京神经科学学会学术年会。北京市龙泉宾馆。2023年8月26日。

2.  Renxi Wang. As a Keynote Speaker. Report:BC094916 suppressed multiple myeloma cell xenograft tumor by down-regulatingCreb1 and Bcl2 transcription. The 3rd SYMPOSIUM ON WORLD CANCER RESEARCH (SWCR2023). Hyatt Regency Tokyo, Tokyo, Japan. Mar 27th-29th, 2023.

3.  Renxi Wang. As a Keynote Speaker. Report: Risk and protective factors for COVID-19. 2ndInternational Conference on Microbiology & Infectious Diseases. Dubai, UAE.November 21-22, 2022.

4.  Renxi Wang. As a Keynote Speaker. Report:Mendelian randomization study updates the effect of 25-hydroxyvitamin D levelson the risk of multiple sclerosis. The 8th Int'l Neurology and NeurosurgeryConference (NeuroConf 2022). Grand Link Hotel, Guilin, China. Dec 16-18, 2022.

5.  Renxi Wang. As a Keynote Speaker. Report:The role of Stch (Hspa13) in plasma cells and lupus mouse. The 6th Int'lConference on Inflammation Research (CIR 2021). Fortune Hotel Xiamen. Xiamen,China. Nov 26-28, 2021.

6.  王仁喜。分会报告：脑重大疾病免疫学机制。北京国际青年创新发展论坛生物医药平行论坛暨首都医科大学第二届国际青年学者论坛脑重大疾病基础临床转化与适应医学分论坛。首都医科大学第二教学楼第78教室，北京，中国，2021年10月12-13日。

7.  王仁喜。分会报告：热休克蛋白Hspa13在浆细胞产生和抗体分泌中的作用及机制。2021生物医药产业大会（第十届国际抗体大会）。大连国际会议中心，大连，中国。2021年9月25-27日。

8.  Renxi Wang. 分会报告主持人并作报告。Report: Regulatory B Cells in Autoimmune Diseases. 第十三届全国免疫学学术大会。上海国际会议中心。2018年11月7-10日。

9.  Renxi Wang. Report: Treatment of autoimmunediseases with anti-IL-39 antibody. BIT¢s 16thannual congress of International Drug Discovery Science & Technology. Jinan,China. Nov 6-8, 2018.

10.WANG RENXI. Report: The Role of Regulatory BCells in Autoimmune Diseases. P099. BIT’s 9th Anniversary World DNADay-2018. Dalian International Conference Center, Dalian, China. April 25-27,2018.

11.WANG RENXI. Report: Mutual inhibition ofXbp-1 and mTOR deletes the effect of IL-1a deficiency on antibody secretion. p116.第十二届全国免疫学学术大会.天津市梅江会展中心。2017年10月26-29日.

12.王仁喜。2017年吉林省医师协会风湿病医师分会第四届年会暨系统性红斑狼疮诊治进展学习班授课：IL-39在狼疮小鼠中的作用及机制研究。吉林-长春。2017-09-01。

13.Renxi Wang. Report: Treatment of autoimmunediseases with anti-IL-39 (p19/Ebi3) antibody. BIT’s 8th Annual InternationalCongress of Antibodies-2016 (ICA-2016).April 25-28, 2016 in Dalian, China

14.王仁喜。分会报告主持人并作报告：T-cell-independent antigens induced two different regulatory B-cellpopulations from splenic marginal zone but not B2 B-cell populations。北京。第十届全国免疫学大会。2015年11月14-17日。摘要：p143.

15.RENXI WANG. Report: Treatment of acute lunginjury with neutralizing anti-human C5a antibody. FUDAN UNIVERSITY SHANGHAI MEDICAL COLLEGE. Internationalworkshop for therapeutic antibody and antigen-antibody complexes basic and application.2015.06.10-12

16.RENXI WANG. Report: Interleukin-35 inducesregulatory B cells that suppress autoimmune disease. Hainan-Haikou.BIT's 5thAnnual World Gene Convention.2014. Nov. 13-16. Abstract: p119.

17. 王仁喜。分会报告题目：代谢型谷氨酸受体3（Grm3）作为抑制性分子调控B细胞的稳态。山东-济南。第九届全国免疫学大会。2014年10月18-21日。

18. Ren-Xi Wang. Report: Genetically Engineered IL-30 (IL27p28) Suppresses ExperimentalAutoimmune Uveitis. ARVO. Florida, USA.May 8-11, 2012.

19. Ren-Xi Wang. Report: Genetically Engineered Novel Il12p40/Il27p28 Heterodimeric ProteinInhibits Lymphocyte Proliferation and Th1 effector Functions. ARVO. Florida, USA.May 1-3, 2011.

1.      美国斯坦福大学发布了最新的“全球前2%顶尖科学家第七版榜单”，在“2023年度科学影响力”榜单中位列第167039位。

2.      美国斯坦福大学发布了最新的“全球前2%顶尖科学家第六版榜单”，在“2022年度科学影响力”榜单中位列第157582位。

3.      2022年度首都医科大学自然科学奖二等奖，项目名称：COVID-19易感、严重性及后遗症的生物信息学分析。获奖人：王仁喜，粟文婷，朱改只，徐雅琪，张敏，高冉、曾琦。授奖机构：首都医科大学。2023年9月7日。

4.      2021年度首都医科大学自然科学奖三等奖，项目名称：B细胞分化、发育及功能。获奖人：王仁喜、粟文婷、朱改只、周珊、徐雅琪。授奖机构：首都医科大学。2022年9月9日。

5.      Awarded to Professor Renxi Wangfor their important contribution to the quality of our publication OncologyLetters on 15/08/2021.

6.      Awarded to Professor Renxi Wangfor their important contribution to the quality of our publication MolecularMedicine Reports on 22/07/2021.

7.      Awarded to Professor Renxi Wangfor their important contribution to the quality of our publication MolecularMedicine Reports on 28/01/2021.

8.      This certificate is awarded to RenxiWang for serving as a reviewer for Journal of Cellular and Molecular Medicine.28 February 2021.

9.      Certificate of Excellence inReviewing awarded to Professor Renxi Wang for their important contribution tothe quality of our publication Oncology Letters on 10/01/2019.

10.   Certificate of Excellence inReviewing awarded to Professor Renxi Wang for their important contribution tothe quality of our publication Molecular Medicine Repots on 10/02/2019.

11.   Certificate of Excellence inReviewing awarded to Professor Renxi Wang for their important contribution tothe quality of our publication Experimental and Therapeutic Medicine on24/01/2019.

12.   Outstanding contribution inreviewing in recognition of the contributions made to the quality of thejournal (Molecular Immunology). March,2018.

社会及学术兼职：

兼任癫痫病临床医学研究北京市重点实验室学术委员会委员（2024.03.22-2027.03.21）

兼任第一届北京神经科学学会癫痫专业委员会委员（2023.08.26-2026.08.25）

兼任首都医科大学北京脑重大疾病研究院第五届学位委员会委员（2023-2026）

兼任首都医科大学北京脑重大疾病研究院第四届学位委员会委员（2019-2022）

兼任第六届中国免疫学会基础免疫分会委员（2023.03.03-2027.03.02）

兼任中国免疫学会会员

兼职下列杂志编委:

1.      2016 Annals of Clinical CaseReports for Allergy & Immunology Case reports

http://anncaserep.com/allergy&immunology.php

2.      2016 Indian Journal of Immunologyand Respiratory Medicines

https://www.innovativepublication.com/editorial_board.php?jid=52 

3.      2016 Austin Journal of Clinical Immunology

http://www.austinpublishinggroup.com/clinical-immunology/editorialboard.php

4.                  2016 JSM Renal Medicine

http://www.jscimedcentral.com/RenalMedicine/editors.php

5.      2016 Remedy Open Access Journalfor Allergy & Clinical Immunology section.

兼职下列杂志副主编（Associate Editor）:

1.    Frontiers in Nutrition (2022 May)

2.    Frontiers in Genetics (2022 May)

兼职下列杂志Review Editor

1.      Frontiers in Ophthalmology -Inflammatory Eye Diseases

兼职下列杂志审稿人:

1.      Medicine (2025 Jan)

2.      Immunology (2024 Feb)

3.      HELIYON (2023 Jan)

4.      Clinical and TranslationalMedicine (2022 Dec)

5.      Neurobiology of Disease (2022 Dec)

6.      Frontiers in Immunology (2022 Nov)

7.      Journal of Medical Virology (2022Jun)

8.      Immunity, Inflammation and Disease(2022 Jun)

9.      Frontiers in Nutrition (2022 May)

10.   Alzheimer's & Dementia（2021 Dec）

11.   J Leukocyte Biol（2021 Sep）

12.   Frontiers in Genetics（2021 May）

13.   Biomedical Reports (2021 Apr)

14.   Molecular and Clinical Oncology(2021 Mar)

15.   Autoimmunity (2019 Sep)

16.   Journal of Immunology Research(2019 Jun)

17.   Mol Med Rep (2019 Feb)

18.   Oncology Letters (2019 Jan)

19.   Experimental and TherapeuticMedicine (2018 Nov)

20.   Acta Biochimica et BiophysicaSinica (2018 Jun)

21.   Eur J Inflammation (2018 May)

22.   Mediators of Inflammation (2018Feb)

23.   Mol Immunol (2017 Dec)

24.   Oncotarget（2017）

25.   Remedy Open Access（2016）

26.   Annals of Infectious Disease and Epidemiology（2016）

27.   BioMed Res Int. (2016)

28.   Indian Journal of Immunology andRespiratory Medicines（2016）

29.               J Rheumatic Dis Treatment（2016）

30.               Int J Virol AIDS（2016）

31.               Int J Immunother Cancer Res（2016）

32.               Int Scholars J（2015）

33.               Cell Mol Immunol（2015）

34.               J Immunity Geneal（2015）

35.               J Cell Mol Med（2015）

36.               《中国免疫学杂志》（2015）

兼职下列基金评审:

1.      北京海外学人中心北京人才项目评审会议专家评委（2024）

2.      国家万人计划青年拔尖人才项目会议评审（2022）

3.      北京市自然科学基金通讯评审（2020）

4.      国家自然科学基金通讯评审（2017）

5.      Czech Science Foundation通讯评审（2016）

申请的中国专利：

1.      邢陈; 宋伦; 王仁喜; 黄欣; 崔皓然; 刘琨; 文青。过表达Hspa13基因的MZ B细胞及其应用。专利申请号：CN202411400523.5。申请（专利权）人：中国人民解放军军事科学院军事医学研究院。申请日期：2024年10月09日。

2.      王仁喜，粟文婷，徐雅琪，张敏，朱改只，高冉，曾琦，邱金明，卞子晴。一种新型系统性红斑狼疮小鼠模型及其应用。专利申请号：202410619590.X。申请（专利权）人：首都医科大学，首都医科大学脑重大疾病研究中心。申请日期：2024年05月20日。

3.      王仁喜，粟文婷，徐雅琪，张敏，朱改只，高冉，曾琦，邱金明，卞子晴。一种基于FAM210B基因的多发性骨髓瘤诊断试剂盒。专利申请号：202410619518.7。申请（专利权）人：首都医科大学，首都医科大学脑重大疾病研究中心。申请日期：2024年05月20日。

4.      王仁喜，粟文婷，徐雅琪，张敏，朱改只，高冉，曾琦，邱金明，卞子晴。一种基于FAM210B基因的系统性红斑狼疮疾病诊断试剂盒。专利申请号：202410619489.4。申请（专利权）人：首都医科大学，首都医科大学脑重大疾病研究中心。申请日期：2024年05月20日。

5.      王仁喜，粟文婷，张敏，朱改只，高冉，曾琦，邱金明，卞子晴。一种基于C15orf39基因的系统性红斑狼疮诊断试剂盒。专利申请号：202410598008.6。申请（专利权）人：首都医科大学，首都医科大学脑重大疾病研究中心。申请日期：2024年05月15日。

6.      王仁喜，粟文婷，张敏，朱改只，高冉，曾琦，邱金明，卞子晴。一种基于C10orf143基因的系统性红斑狼疮诊断试剂盒。专利申请号：202410605174.4。申请（专利权）人：首都医科大学，首都医科大学脑重大疾病研究中心。申请日期：2024年05月16日。

7.      王仁喜，粟文婷，朱改只，周珊，徐雅琪，高冉，张敏，曾琦。一种基于Cxorf65基因的脑卒中诊断试剂盒。专利申请号：202211389939.2。申请（专利权）人：首都医科大学，首都医科大学脑重大疾病研究中心。申请日期：2022年11月08日。

8.      王仁喜，粟文婷，周珊，朱改只，徐雅琪，高冉，张敏，曾琦。一种基于FAM124A基因的多发性骨髓瘤诊断试剂盒。专利申请号：202211389938.8。申请（专利权）人：首都医科大学，首都医科大学脑重大疾病研究中心。申请日期：2022年11月08日。

9.      王仁喜，粟文婷，周珊，朱改只，徐雅琪，高冉，张敏，曾琦。一种治疗多发性骨髓瘤的抑制剂。专利申请号：202211389915.7。申请（专利权）人：首都医科大学，首都医科大学脑重大疾病研究中心。申请日期：2022年11月08日。

10.   王仁喜，粟文婷，周珊，朱改只，徐雅琪，高冉，张敏，曾琦。一种过表达Fam124a的多发性骨髓瘤细胞株SP 2/0及其应用。专利申请号：202211389773.4。申请（专利权）人：首都医科大学，首都医科大学脑重大疾病研究中心。申请日期：2022年11月08日。

授权的国际专利：

1.     Charles Egwuagu, Ren-Xi Wang, Cheng-Rong Yu.METHODS OF PRODUCING AND USING REGULATORY B-CELLS. United States Patent. PatentNo.: US 9,629,897 B2. Date of Patent: Apr. 25, 2017. PCT No.:PCT/US2013/036175. Date: Oct. 23, 2014.

2.      Han G, Chen G, Kang C, Xiao Y, XieX, Wang R, Lang X, Xiao H,Hou C,Feng J, Jiang X, Zhao Z, Li Y, Shen B. Human Tim-3 fusion protein capableof blocking Tim-3 signaling pathway. United State Patent. 2017.05.09; 美国，US 9644020 B2. PCT No.: PCT/CN2015/000031. Date: Oct. 7, 2016.

授权的中国专利：

1.      邢陈，宋伦，王仁喜，侯春梅，黄欣，李葛，吴霖，争鸣。一种HSPA13基因表达载体及其构建方法和应用。申请（专利权）人：中国人民解放军军事科学院军事医学研究院。专利号：ZL 2021 1 0011566.4。申请日期：2021.01.06。授权日：2022.06.28。

2.      王仁喜，肖鹤，韩根成，陈国江，黎燕，沈倍奋，侯春梅，王小茜，魏寅祥，刘晓玲，张玉。P19/Ebi3复合物及其多克隆抗体在系统性红斑狼疮诊治中的应用。专利号：ZL 2015 1 0555637.1。专利权人：中国人民解放军军事医学科学院基础医学研究所。授权日：2018年04月27日。

3.      王仁喜，黎燕，肖鹤，韩根成，陈国江，侯春梅，沈倍奋，马宁，邢陈。一种获得自身反应性B细胞的方法。专利号：ZL 2013 1 0244248.8。专利权人：中国人民解放军军事医学科学院基础医学研究所。授权日：2017年12月01日。

4.      韩根成，陈国江，石新慧，王海滨，肖燕，谢晓玮，肖鹤，王仁喜，王位，冯健男，黎燕，沈倍奋。血清中可溶性Tim-3蛋白作为诊断慢性肾病的标志物。专利号：ZL 2016 1 0292904.5。专利权人：中国人民解放军军事医学科学院基础医学研究所。授权日：2017年05月31日。

5.      陈国江，韩根成，黎燕，沈倍奋，洪海燕，王仁喜，肖鹤，王一，王柯，候春梅。人白介素-1受体拮抗剂的新用途。专利号：ZL 2013 1 0724082.X。专利权人：中国人民解放军军事医学科学院基础医学研究所。授权日：2017年02月08日。

6.      侯春梅，韩根成，陈国江，王仁喜，肖鹤，黎燕，冯健男，沈倍奋。一种基于DNAH5 基因的结肠癌诊断试剂盒。专利号：ZL 2015 1 0070003.7。专利权人：中国人民解放军军事医学科学院基础医学研究所。授权日：2016年09月14日。

7.      韩根成，陈国江，蒋兴伟，王仁喜，肖鹤，侯春梅，于佳卉，赵智，冯健男，黎燕，沈倍奋。一种能阻断Tim-3信号通路的人Tim-3融合蛋白。专利号：ZL 2014 1 0036782.4。专利权人：中国人民解放军军事医学科学院基础医学研究所。授权日：2016年08月24日。

8.       韩根成，陈国江，康春燕，肖燕，谢晓玮，王仁喜，解立新，郎小玲，肖鹤，侯春梅，冯健男，蒋兴伟，赵智，黎燕，沈倍奋。一种检测TIM-3试剂盒及其使用方法。专利号：ZL 2014 1 0036781.X。专利权人：中国人民解放军军事医学科学院基础医学研究所。授权日：2016年08月17日。

9.       王仁喜；黎燕；肖鹤；韩根成；陈国江；侯春梅；沈倍奋；马宁；邢陈。一种治疗多发性硬化的药物组合物。专利号：ZL 2013 1 0120331.4。专利权人：中国人民解放军军事医学科学院基础医学研究所。授权日：2016年08月03日。

10.    王仁喜；黎燕；肖鹤；韩根成；陈国江；侯春梅；沈倍奋；马宁；邢陈。一种治疗系统性红斑狼疮的药物组合物. 专利号：ZL 2013 1 0120334.8. 专利权人：中国人民解放军军事医学科学院基础医学研究所。授权日：2015年04月01日

11.    陈国江；韩根成；王仁喜；肖鹤；侯春梅；黎燕；冯建男；沈倍奋；王一；王珂；刘桂君。一种抗肿瘤蛋白质。专利号：ZL 2013 1 0015845. 3. 专利权人：中国人民解放军军事医学科学院基础医学研究所。授权日：2014年05月21日

12.    黎燕，沈倍奋，王建安，王仁喜，韩根成，宋伦，钱家华，吴小兵，董小岩，曹晖。用于治疗和预防I型糖尿病的重组腺相关病毒及其用途。专利号：ZL 2003 1 0115504X. 专利权人：中国人民解放军军事医学科学院基础医学研究所，本元正阳基因技术股份有限公司。授权日：2009年06月03日